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Selected  regions of the  Hml muscarinic  cholinergic 
receptor  were  mutated  to  analyze  the molecular mech- 
anisms of agonist-induced  receptor internalization  (or 
sequestration).  The  wild-type  and  mutant Hml genes 
were  expressed,  using pSG5, in  U293  human  kidney 
cells. Whereas surface  receptor  density  measured  with 
the polar tracer N-[3H]methylscopolamine was  rapidly 
reduced  by  carbachol  exposure,  total  receptor  content 
measured  with  [3H]quinuclidinyl  benzilate  did  not de- 
cline  for  at  least  24  h,  indicating  the absence of exten- 
sive receptor down-regulation in U293 cells. Car- 
bachol stimulation of phosphatidylinositol turnover 
paralleled  receptor  internalization,  both  with ECso val- 
ues of 10-20 PM. Furthermore, a D71N  point  mutation 
that prevented  receptor  activation  also  abolished car- 
bachol-induced  receptor internalization,  indicating 
that receptor activation (but not necessarily second 
messenger  stimulation)  was  required  for  internaliza- 
tion. Truncation of the COOH-terminal tail (K447 
trunc)  and point  mutations of several  potential Ser and 
Thr phosphorylation sites  to Ala failed  to  affect  recep- 
tor activation  and  internalization.  In  contrast,  partial 
deletions of the  third  intracellular loop (i3) (TyrZo8- 
Thr3“)  resulted  in  receptor  mutants  deficient  in  ago- 
nist-induced  receptor internalization/sequestration. 
Various  deletions  caused either complete  loss of inter- 
nalization (d 232-358) or impaired internalization, 
ranging  from 10 to 30% over 2 h, whereas  wild-type 
Hml internalized  to -50%. Whereas  the  reason  for  the 
observed  differences  among the deficient  deletion mu- 
tants  remains  unclear,  the  initial  rate of N-[3H]methyl- 
scopolamine binding loss from the cell surface was 
much  slower  than  that of wild-type Hml in  each case. 
The deletion of only  one  single  domain, 284-292 
(SMESLTSSE), in  the middle of i3 was consistently 
associated  with impaired  internalization.  Domain 
284-292 is partially  conserved  among closely related 
muscarinic  receptors,  whereas most of the  remainder 
of i3 is not  (except for  the i3 membrane  junctions),  and 
similar  Ser-  and  Thr-rich  regions  are  present  in  many 
other G protein-coupled  receptors. We propose that a 
small  receptor  domain  in  the  middle of the  i3 loop of 
Hml is involved in agonist-induced  receptor internal- 
ization. 
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The  activity of membrane-bound receptors is regulated by 
several  processes,  including desensitization,  internalization/ 
sequestration, recycling, and down-regulation. Receptor-me- 
diated endocytosis, as a major pathway of internalization, 
involves the  formation of coated  pits  and  interactions  among 
receptors, adaptins,  and  clathrin (1). Molecular domains re- 
quired for internalization have  been  defined  for  growth factor 
receptors (1-3), the  transferrin receptor (4, 5 ) ,  and  the low 
density lipoprotein  receptor (6). Whereas a  universal consen- 
sus sequence could not be derived, the  results suggested that 
intracellular domains near the transmembrane helices con- 
taining  an  aromatic residue  (especially tyrosine)  are required 
for internalization (1-6). Furthermore,  internalization  path- 
ways can be distinguished by their  requirement for receptor 
phosphorylation ( 5 ) .  Internalized receptor may either recycle 
to  the cell surface or proceed to a lysosomal compartment for 
destruction (down-regulation). Different molecular domains 
are  thought  to cause  receptor internalization  and down-regu- 
lation (l), whereas little  is known about  the  requirements for 
receptor recycling. 
Most members of the G protein-coupled receptor family 
also  undergo internalization/sequestration, recycling, and 
down-regulation; however, the molecular mechanisms of these 
processes remain largely unexplored, and no receptor domains 
required for cellular trafficking had been identified as yet. 
Valiquette et al. (7) prepared mutants of the human (I2- 
adrenergic  receptor by replacing  Tyr350 and  Tyr354 with ala- 
nine, but these point mutations failed to alter the rapid 
agonist-induced internalization process, whereas the subse- 
quent  step of down-regulation was reduced. Receptor inter- 
nalization is tightly associated  with  receptor activation; how- 
ever, the role of each of the consecutive activation  steps is 
not  understood, e.g. at the level of the receptor, the G protein, 
and  the second  messenger. On  the basis of deletion  analyses, 
Cheung et al. (8) postulated  that  the receptor  regions of the 
&receptor involved in functional coupling to G, are also 
required  for agonist-promoted  sequestration.  In  contrast, p2- 
receptors  that  are functionally  uncoupled or impaired because 
of genetic  lesions of G, (9) or substitution  mutations of the 
receptor domains involved in G protein coupling (10) still  are 
able to sequester normally. Therefore, activation of the G 
protein may not have  been  a  prerequisite  for  receptor inter- 
nalization/sequestration. 
Muscarinic cholinergic  receptor internalization  and down- 
regulation have been studied  in  intact cells with the use of N -  
[3H]methylscopolamine ([3H]NMS)’  as  the polar tracer with 
access to only the cell-surface  receptor and [3H]quinuclidinyl 
’ The abbreviations used are: [‘HINMS, N-[3H]methylscopolam- 
ine; [‘HIQNB, [‘H]quinuclidinyl benzilate; PI, phosphatidylinositol; 
PAO, phenylarsine oxide; PMA, phorbol 12-myristate 13-acetate; 
GPCRs, G protein-coupled receptors. 
13406 
Loop i3 of Hrnl Regulates  Receptor  Trafficking 13407 
benzilate ([3H]QNB) as  the lipophilic tracer for assay of total 
receptor content (11-14). In  this study, we do not distinguish 
between receptor internalization and sequestration; the  term 
"internalization" is subsequently used to indicate loss of [3H] 
NMS cell-surface binding without  concomitant loss of t3H] 
QNB binding. 
The muscarinic receptors ml, m3, and m5 are coupled to 
phosphatidylinositol turnover (15, 16), and stimulation of 
protein kinase C by phorbol esters causes muscarinic receptor 
phosphorylation (17) and rapid receptor internalization as 
observed in several studies (12-14, 18). However, protein 
kinase C activation may have no effect (19) or may even 
inhibit  internalization in some tissues (20). An essential role 
for protein kinase C activation  in  internalization is therefore 
questionable. Using Y1 adrenal carcinoma cells transfected 
with the mouse m l  gene, Shapiro and  Nathanson (21) found 
that receptor mutants with large deletions of the  third  intra- 
cellular loop (i3) internalize normally, but that the largest 
deletion mutant  (d 221-343) shows less down-regulation upon 
carbachol treatment. We have constructed mutants of the 
human ml  gene (which is nearly identical to the mouse gene) 
with an even larger deletion of the i3 loop, and  the deletion 
mutant (d 232-358) reaching closest to  the COOH-terminal 
end of the i3 loop  was no longer capable of agonist-induced 
internalization, although stimulation of PI turnover was un- 
affected (22). This result suggested a role for the i3 loop in 
receptor internalization, and  it dissociates G protein  activa- 
tion from internalization. 
In  this study, the relationship between receptor internali- 
zation and activation of Hrnl was studied with a D71N point 
mutation that was previously shown to bind agonist and 
antagonist ligands, but  that fails to activate PI turnover upon 
agonist  stimulation (23). Furthermore, we analyzed the mo- 
lecular mechanisms of Hrnl receptor activation and  internal- 
ization with the use of multiple mutants involving the i3 loop 
(positions 208-366) and the COOH-terminal tail (positions 
420-460). The results suggest a  critical role for a domain in 
the i3 loop, whereas none of the potential  Ser or Thr phos- 
phorylation sites studied nor the COOH-terminal tail were 
found to be required in agonist-induced internalization. We 
propose that a small domain in the middle of the i3 loop of 
Hrnl is required for agonist-induced receptor internalization. 
EXPERIMENTAL  PROCEDURES 
Materials-[:'H]NMS (specific activity of 80 Ci/mmol) and [3H] 
QNB (specific  activity of 30 Ci/mmol) were obtained  from Amersham 
Corp. or Du  Pont-New  England Nuclear. All other  reagents were of 
analytical grade quality from  common  commercial  sources (e .g .  phen- 
ylarsine oxide (PAO), the Ca2' ionophore A23187, and phorbol 12- 
myristate 13-acetate (PMA)). Pertussis toxin was purchased from 
List Biological Laboratories (Campbell, CA).  Bal-31 was purchased 
from New England BioLabs, Inc. (Beverly, MA), and restriction 
enzymes were from either Boehringer Mannheim or Bethesda Re- 
search  Laboratories. 
Construction of Vectors Expressing Hrnl  and  Mutants-The gene 
encoding Hml  was obtained  from a human  placental genomic library 
in vector EMBL3  as described previously (22). Deletions of the i3 
domain were introduced after  cutting  the  Gem3/Hml vector at  the 
unique StuI restriction site, at  position 712 (at codon for A&''), 
followed by digestion with  the exonuclease Bal-31 for varying times 
at 4 "C  (22).  The  blunt-ended  product was  self-ligated to yield mu- 
tants with deletions of varying size within the i3 domain (TyrZoX- 
Thr"""). In-frame  mutants were transferred to pSG5 using EarnHI/ 
EcoRI. For the  construction of point  mutations,  Hrnl was transferred 
to  M13mp18  using EamHI/EcoRI,  and  single-stranded  DNA  incor- 
porating dUTP was made (Kunkel method; for general  protocols,  see 
Ref. 24). The desired point mutations were then introduced with 
oligonucleotides (21-24-mers) containing one codon change. Simi- 
larly,  small deletions in i3 were introduced with 30-mer oligonucleo- 
tides,  complementary  to  15 nucleotides adjacent  to  the deletion 
points. A truncation  mutant was obtained by introducing a termina- 
tion codon a t  LYS''~. Each  mutant  Hml gene  was  sequenced before 
transfer  to  pSG5 using EamHIIEcoRI.  The double  deletion mutant 
d 219-231/d 267-293 was prepared by transferring  the  ApaI  restric- 
tion fragment (nucleotides 475-796) of d 219-231 into d 267-293 
using vector Gem3, which lacks ApaI sites. Similarly, the double 
deletion mutant d 267-293/d 344-358 was constructed by exchanging 
the  EclI/EamHI  fragment.  EclI  cuts  at nucleotide  903 and requires 
a plasmid DNA preparation grown in a methylation-deficient  Esch- 
erichia coli strain. To delete sequence 283-293,  we employed an 
inverse  polymerase chain reaction (25)  that  introduces a NarI restric- 
tion site into the deleted sequence (GGCGCC); therefore, 2 amino 
acids  (Gly and Ala) were introduced  into  the deleted sequence. Thus, 
mutant d 284-293 was obtained because GlyZR:' was reintroduced in 
addition to 1 Ala residue for deleted  sequence 284-293. Further 
deletion mutants or double  deletion mutants  at  the 5'-  and 3"sides 
of the newly introduced NarI site were prepared by generating  the 
requisite  fragments of H m l  from NarI to  EamHI  (5') or EcoRI (3') 
with  the use of polymerase chain reaction (26)  and  reinserting  the 
fragment  into  the vector H m l  (d 284-293) cut with NarI and  either 
EamHI or EcoRI. All mutations were verified by sequencing. To 
obtain standardized DNA preparations (-1 mg of DNA) for wild- 
type  pSG5/Hml  and  all  mutants,  plasmid DNA was purified by  LiC1/ 
isopropyl  alcohol and polyethylene glycol 8000 precipitation (24). 
Transfection of Human Kidney Cells  (U293)-U293 cells were 
transfected by the calcium phosphate  precipitation  method (22, 24). 
Briefly, 1.5 X IOfi exponentially growing U293 cells were plated  onto 
10-cm  tissue  culture dishes.  After 24 h,  a precipitate of 6 pg of DNA 
with  calcium phosphate was  added to freshly fed cells. After  4  h of 
incubation a t  37 "C  and a dimethyl sulfoxide shock, the cells were 
allowed to recover, and the binding experiments or PI turnover 
analysis was performed after 48 h. For stable  transfections with pSG5 
containing  the wild-type and  mutant  Hml d 232-358 genes (20 pg/ 
plate), U293 cells were cotransfected with pSv"'" (2 pg/plate). Cell 
clones resistant to the antibiotic G418 (-500 pg/ml) were isolated 
and screened for receptor  expression with  ["HINMS. One  clone each 
expressing -300,000 sites/cell (-1000 fmol/mg of protein) of Hml  
and d 232-358 was selected for further  study. 
Receptor Binding  and  Internalization Assay-For internalization 
assays, we modified the procedure  described previously (22) to  obtain 
more  accurate  results  and  to  permit assay of relatively  small  changes. 
Dishes containing cells transfected with the appropriate receptor 
mutant were pooled 24 h after transfection. The pooled cells were 
replated  onto 12-well cell culture dishes and allowed to  attach over- 
night.  Then  the cells were incubated with or without 1 mM carbachol 
for up  to 2  h and,  in  the case of stably  transfected cells, up  to 24 h. 
After drug  treatment,  the cells were cooled on ice and washed three 
times with ice-cold phosphate-buffered saline to remove residual 
carbachol  remaining  on  the cells. The cells were then  incubated  in 
an isotonic  buffer containing 1.5-2 nM ("HINMS (or 1 nM ['HIQNB 
for total  sites)  at 12 "C  (to  prevent receptor recycling) for 90 min. At 
the  end of the  incubation,  the cells were placed  on ice, removed from 
the wells, and filtered  quickly on glass-fiber filters (SS 32), followed 
by three rapid rinses with phosphate-buffered saline. Six replicate 
independent  samples were assayed for each treatment condition 
(unless  noted  otherwise)  to  obtain  estimates of variability and signif- 
icance of differences. Pretreatment with agents  other  than carbachol 
(PAO,  PMA, forskolin, pertussis  toxin) was as described under "Re- 
sults." 
Displacement binding curves with carbachol (0.01-10 mM) were 
performed a t  a ['HINMS concentration of 0.1 nM. The resultant 
carbachol displacement curves were analyzed with the use of the 
logistic function E = E,,, - E,,, * L/(ICs0 + L) + NSB, where E = 
tracer  bound  (in disintegrations/minute), L = carbachol  concentra- 
tion,  and  NSB = nonspecific binding. The curves were fitted using 
nonlinear regression analysis of the unweighted data with the curve 
fitting program Minim 1.2 (R. 0. Purves,  Department of Pharmacol- 
ogy, School of Medicine, University of Otago, Dunedin, New Zealand). 
PI Turnouer-PI turnover was  measured by the  method of Berridge 
et al. (27)  after labeling the cells with ['HH]myoinositol for 24 h. For 
the  measurements of IP, inositol 1,4-bisphosphate,  and inositol  1,4,5- 
triphosphate, individual dishes of 10-cm diameter were used; for the 
measurement of PI alone, which accounts for most of the inositol 
phosphate 'H activity, six-well cell culture  dishes (well diameter  to 
3.5 cm) were used. Results were expressed as percent of total 'H 
activity in the inositol phosphates, and the percent values were 
compared between carbachol-treated  and  -untreated cells. The follow- 
ing  concentrations of carbachol were used for dose-response  curves 
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TABLE I 
Effect of mutations of Hml on PHINMS binding, carbachol-induced internalization, carbachol  binding, 
and carbachol-induced activation of PI turnover 
Transiently transfected cells were incubated with 1 mM carbachol for 2 h to induce internalization and for 30 min to stimulate PI turnover, 
measured as ['HIIP release. The [3H]NMS concentration was -1.5 nM, except for measuring carbachol binding competition, when 0.1 nM 
["HINMS and carbachol concentrations from 0.01 to 10 mM were  used.  All data are mean f S.D.; number of replicates/experiment are shown 
a t  the  top of the columns. Independent experiments are listed separately, or the number of experiments is indicated next to  the results if all 
results are averaged. 
[3H]NMS 
( n  = 4-6) binding) IC, over control (no carbachol) 
Carbachol pretreatment Stimulation of [3H]IP 
(W of control [3H]NMS Carbachol binding release (1 mM carbachol) 
( n  = 6)  (Emax) (n= 3) 
Nontransfected U293 cells 
D71N 
Wild-type Hml 
K447 trunc 
d 219-231 
d 344-358 
d 267-293 
d 267-292 
d 265-274 
d 276-282 
d 284-2936 
d 256-293' 
d 284-3036 
d 255-310 
d 247-304 
d 242-312 
d 220-314 
d 219-333 
d 220-349 
d 232-358 
d 219-231/d267-293 
d 267-293/d  344-358 
d 284-293/d  344-358' 
fmollmg protein 
32 f 1.4 (n = 2) 
792 f 347 ( n  = 23) 
676 f 34 
485 f 132 (n = 3) 
814 f 56 (n = 2) 
580 f 99 (n = 2) 
710 f 222 (n  = 4) 
912 f 67 
1045 f 101 ( n  = 2) 
295 f 66 ( n  = 2) 
1332 f 35 (n = 3) 
675 f 54 
282 f 16 
650 f 138 (n  = 3) 
567 f 65 
389 f 121 (n = 2) 
873 f 112 (n = 4) 
387 f 105 ( n  = 5) 
217 f 18 
770 f 320 ( n  = 7) 
867 f 158 ( n  = 2) 
1296 f 239 (n = 2) 
286 f 23 
56 f 7 
55 f 8 (n = 14) 
91 f 8  
67 f 4,63 f 6,66 f 
9, 52 -+ 2 
49 f 3,64 f 6 
57 f 5,67 f 6 
87 f 8,91 f 12,85 f 
4,93 f 10 
85 f 7 
49 f 2,60 f 4 
51 f 3,64 f 4 
77 f 7,85 f 13, 76 f 
9,87 f 9 
70 f 3 
72 f 7 
77 f 8,86 f 5 
83 f 6,61 f 8 
85 f 8,76 f 3 
61 f 3,60 f 4,68 f 4 
80 f 9 
76 f 11 
94 f 7, 107 f 7,103 
f 2  
87 f 5,86 f 4 
95 f 7, 95 f 9 
67 f 6,68 f 7 
mM 
2.7 f 0.9 ( n  = 5)" 
0.44 f 0.05 12.6 f 2.7 ( n  = 11) 
3.5 f 0.1" 
0.18 f 0.05 11 2 0.4 
9 f 0.3 ( n  = 2) 
11 k 2.5 ( n  = 2) 
13 f 0.3 
11 1 0 . 2  
12 f 0.7 
9 f 2 ( n = 2 )  
10.7 f 0.3 ( n  = 2) 
12 f 0.1 (n = 2) 
0.74 f 0.2 8.9 f 0.3 (n = 2) 
11.2' 
0.2' 11' 
1.8' 15 1 6 (n = 3)' 
" Nontransfected U293 cells and cells transfected with the inactive receptor mutant D71N  (20) showed significantly lower [3H]IP release 
in the absence of carbachol compared with cells transfected with active receptor (wild-type Hml  and all other  mutants). Whereas carbachol 
stimulation in native cells and D71N cells was clearly measurable, absolute values of [3H]IP release were greater by a factor of >10 in cells 
transfected with active receptors. 
' These  mutants were prepared by polymerase chain reaction using a NarI restriction site, thereby introducing GA into the deletion site. 
' These mutants were characterized in a previous paper (22). 
(IP measured only): 3,10,  30,100, and 1000 PM. The  data were fitted 
to the equation E = Emax * L/E,,, + L) where E = stimulation of IP 
release over control values and Emax = maximum stimulation. The 
results were fitted with the Minim 1.2 program. 
RESULTS 
Stably Transfected U293 Cells Expressing Hml  and d 232- 
358-The binding of [3H]NMS (1 nM) and [3H]QNB to cells 
transiently transfected with wild-type Hml was differently 
affected by exposure to 1 mM carbachol. Whereas  [3H]NMS 
binding was reduced to -50% of control (Figs. 1 and 2), [3H] 
QNB binding was not significantly affected (94 f 7% com- 
pared to no carbachol pretreatment  at 20 min). 
To investigate the time course of [3H]NMS and [3H]QNB 
binding during exposure to carbachol for up to 24 h, U293 
cells stably transfected with wild-type Hml and  the d 232- 
358 mutant were selected (-300,000 sites/cell). Previous work 
had indicated that loss of [3H]NMS binding caused by car- 
bachol pretreatment was independent of receptor density over 
at least a 10-fold range and that the d 232-358 mutant, 
although active in PI turnover, did not  internalize or sequester 
any [3H]NMS-binding sites for up to 2 h (19). As in the 
transiently  transfected cells (19), carbachol caused rapid loss 
of [3H]NMS binding over 2 h, whereas no further loss was 
observed for up to 24 h (54 f 3%) in the cells stably trans- 
fected with wild-type Hml.  This result was surprising as one 
would have expected additional down-regulation after the 
initial rapid loss of cell-surface receptors. Accordingly, [3H] 
QNB binding to all Hml receptors present did not change 
substantially upon carbachol treatment over the  entire assay 
period (84 f 5% of control at  24 h). In contrast, binding of 
both  [3H]NMS and [3H]QNB to  the d 232-358 mutant recep- 
tor was unaffected by carbachol pretreatment over 5 h (98 f 
9 and 106 f 3%, respectively), confirming the lack of receptor 
sequestration (22), but it actually increased over 24 h (148 f 
3 and 187 f 21%, respectively). Because muscarinic receptor 
number may actually increase during prolonged exposure to 
carbachol, we were unable to study receptor down-regulation 
in this cell line, and agonist exposure was limited to 2 h or 
less in subsequent experiments. Furthermore, all subsequent 
experiments were performed in transiently transfected cells. 
In 23 experiments, variability of expression of Hml was 792 
f 347 fmol/mg of protein (fS.D.), which  was acceptable for 
this study, yielding an average loss of [3H]NMS binding to 55 
& 8% of control (14 experiments)  after  a  2-h treatment period 
with 1 mM carbachol (Table I). 
Modulation of Carbachol-induced PHJNMS Binding Loss 
by PAO, Pertussis Toxin, and PMAIA23187-The metabolic 
poison PA0 has been shown to  inhibit agonist-induced recep- 
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tor internalization (28). Upon pretreatment of Hml-trans- 
fected U239 cells with 100 p~ PA0 for 5 min, followed by 
addition of 1 mM carbachol for 2  h, ['HINMS receptor loss 
was significantly reduced, with 81 f 9 and 83 f 4% (&S.D., n 
= 6,  two experiments) of tracer binding remaining relative to 
no carbachol treatment.  Without PAO, [3H]NMS binding was 
reduced to 55 f 8% (Table I) by carbachol. This result is 
consistent with the hypothesis that loss of [3H]NMS binding 
represents an internalization process that may be in part 
energy-dependent. Pretreatment of U293 cells with  pertussis 
toxin (1 pg/ml) for 6  h failed to affect 1 mM carbachol-induced 
receptor internalization.  [3H]NMS binding was 106% of con- 
trol after  pertussis treatment alone, whereas additional car- 
bachol treatment for 30 min resulted in receptor reduction to 
61 f 3%. In this same experiment, [3H]NMS binding was 
reduced to 57 f 4% by carbachol alone, without pertussis 
treatment. Furthermore,  pertussis  toxin (100 ng/ml for 6 h) 
did  not affect carbachol-stimulated PI  turnover  in U293 cells 
transfected with wild-type Hml (pertussis toxin alone: 1.2- 
fold stimulation of [3H]IP release; 1 mM carbachol alone: 
10.1-fold; carbachol + pertussis toxin: 11.9-fold). 
The effects of exposure of the cells to  both PMA (10 WM) 
and A23187 (30 pM)  for 30 min were tested after transient 
transfection with wild-type Hml  and deletion mutant d 232- 
358. In neither case was a significant change from control 
["HINMS binding detectable (wild-type: 99 k 3 and 99 f 6%, 
respectively; d 232-358:  94 f 7 and 89 f 7%, respectively; f 
S.D., n = 6, two independent  experiments). 
Lack of Internalization of Inactive Mutant  D71N"Point 
mutation of  Asp71 to results  in  a mutant (D71N) that 
binds ['HINMS and carbachol similar to  the wild type, but is 
completely inactive in  stimulating PI turnover (23). We have 
confirmed this result (Table  I), achieving transient transfec- 
tion efficiencies similar to those of the wild type. Furthermore, 
carbachol-stimulated PI turnover was indistinguishable from 
that caused by the native muscarinic receptor present  in U293 
cells (32 fmol/mg of protein).  The approximately 3-fold stim- 
ulation of PI turnover in nontransfected and D71N-trans- 
fected U293 cells was readily distinguishable from that occur- 
ring in  cells transfected with wild-type Hrnl  and active recep- 
tor  mutants  that displayed a severalfold higher base line of 
[''HIIP release and a -10-fold stimulation after carbachol 
pretreatment (Table I, Footnote a). Hence, mutant D71N  was 
inactive, and  it was found to be also resistant  to carbachol- 
induced receptor internalization  (91 -+ 8%) (Table I). 
Truncation of COOH Terminus-We introduced a  termi- 
nation codon at Lys447 to yield mutant K447 trunc. The 
truncation position was chosen to eliminate  any  putative  Ser 
and Thr phosphorylation sites in the COOH-terminal tail 
while preserving receptor regions with possible functions  in 
G protein  activation. Mutant K447 trunc yielded productive 
["HINMS binding comparable to  that of the wild type, and 
ICbo values for carbachol displacement of ['HINMS were 
similar. Repetitive measurements of carbachol ICso values for 
the wild-type receptor yielded values ranging from 0.3 to 1 
mM, with slope factors varying from n = 0.5 to 0.8. One 
possible cause for this fluctuation could be a variable extent 
of G protein association of transiently transfected Hml recep- 
tors. As a consequence, a small variation of the carbachol ICso 
values may not indicate any significant change of carbachol 
binding parameters. Mutant K447 trunc was also maximally 
active in  carbachol-stimulated PI turnover, and  it did inter- 
nalize to  an  extent similar to  that of the wild type (Table I). 
Finally, the time course of internalization after  15,30,60,  and 
120 min of carbachol (1 mM) exposure was indistinguishable 
from that of the wild type (data not  shown). 
Deletion Analysis of i3 Loop Domains Involved  with Hml 
Internalization-Our previous results indicated that deletion 
of a large portion of i3 leads to reduced loss of [3H]NMS 
binding upon carbachol pretreatment, although the  mutant 
receptors are still fully active in  stimulating PI turnover (22). 
Furthermore, the ECs0 values for carbachol stimulation of PI 
turnover are only marginally changed (22). Similarly, all 
tested deletion mutants of i3 listed in  Table  I were maximally 
effective in [3H]IP release upon exposure to 1 mM carbachol. 
Complete dose-response curves were performed with several 
deletion mutants (d 219-231, d 344-358, d 219-333, and d 
232-358), and in each case, the ECSo values were not signifi- 
cantly different from that of the wild-type receptor (10-20 
WM) (data not  shown). Finally, carbachol binding was mini- 
mally affected where tested  (Table I). Therefore, the remain- 
der of this study was performed with 1 mM carbachol, which 
maximally activates PI turnover. 
Among the  three large deletions studied (d 232-358, d 220- 
349, and d 219-333), d 232-358  was unresponsive to carbachol 
pretreatment, whereas d 220-349 and d 219-333  were partially 
defective (22). With  the use of a more precise binding assay, 
these  results were confirmed for d 232-358  (102 f lo%, n = 
16, [3H]NMS binding after 2 h of carbachol treatment relative 
to control) and for d 220-349 and d 219-333, which showed 
an intermediate loss of ['HINMS binding (Table I). The 
difference between these latter two mutants  and d 232-358 
was significant. 
To define relevant domains of the i3 loop, we tested smaller 
deletions obtained by Bal-31 exonuclease digestion of Hml 
cut at A r F 1  by StuI. Surprisingly, four smaller deletion 
mutants tested (d 220-314 to d 255-310)  were still partially 
defective in  their response to carbachol, and they internalized 
to  an  extent similar to  that of d 220-349 and d 219-333 (Table 
I). We thus selected even smaller deletions, and  an unexpected 
result was obtained  mutants d 267-293 and d 267-292  were 
again nearly unresponsive to carbachol in the [3H]NMS  bind- 
ing assay. Taken all measurements together, the difference 
between [3H]NMS binding loss of d 267-293 (88 f 9%, f 
S.D., n = 25, 2 h of carbachol treatment)  and control binding 
was highly significant ( p  5 0.0001, t test),  as was the differ- 
ence between d 267-293 and  the unresponsive mutant d 232- 
358 (see above). Therefore, d 267-293 still showed a statisti- 
cally significant, but overall rather small, net loss of ['HI 
NMS binding. We then prepared three small deletion mutants 
within sequence 267-283. Whereas  d 265-274 and d 276-282 
were indistinguishable from wild-type Hml, d 284-293 was 
again deficient in agonist-induced internalization (Table I). 
These results indicate that domain 284-292 is required for 
normal internalization. There was a small difference between 
d 267-293 and d 284-293, which suggested that different or 
additional mechanisms may play a role. However, a slightly 
larger deletion (d 256-293)  was similarly deficient compared 
with d 284-293. Therefore, the small difference between d 
267-293 and  the  other intermediate deletion mutants could 
not be associated with any specific receptor domain. 
The difference between all deletion mutants with interme- 
diate loss of ['HINMS binding and d 232-358 with no appar- 
ent [3H]NMS loss upon carbachol exposure suggested two 
hypotheses. First, sequence 219-231 could serve to prevent 
internalization or mediate recycling, or second, sequence 349- 
358 could mediate an additional, slower internalization path- 
way or prevent recycling. We therefore  tested the behavior of 
the small deletion mutants d 219-231 and d 344-358. Loss of 
[3H]NMS binding upon carbachol exposure was similar to  the 
wild type  in each case. However, any effect of these regions 
may not be detectable  under the assay conditions. Therefore, 
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we also constructed the double deletion mutants d 219-231/d 
267-293, d 267-293/d  344-358, and d 284-293/d  344-358. In 
each case, introduction of the small deletion at  the junctions 
of the i3 loop had  little overall effect on the internalization of 
mutants d 267-293 and d 284-293 (Table I). Therefore, we 
were unable to demonstrate that sequences 219-231 and 349- 
358 play a role in receptor trafficking. 
Time  Course of Carbachol-induced Internalization-Several 
processes could contribute to loss of [3H]NMS binding upon 
carbachol exposure. We therefore studied the time course of 
["HINMS binding after carbachol pretreatment from 15 min 
to 2 h (Fig. 1). The wild-type receptor rapidly reached maxi- 
mum internalization at  30-60 min, with 55% of control 
reached as early as 15 min after carbachol addition. Mutant 
d 232-358 did not show any loss of [3H]NMS binding (30 min 
and 2 h) or only minimal internalization (15- and 60-min time 
points) (Fig. 1A). Mutant d 267-293 did internalize to a small 
extent at  all time  points (p < 0.05 at 60 and 120 min) (Fig. 
1B). Three mutants with intermediate deletions were also 
selected for the initial  time course study. All three  (d 220- 
314, d 247-304, and d 219-333) were strongly impaired in 
carbachol-induced internalization over the initial 30 min com- 
pared to the wild type, but  these receptor mutants continued 
t o  disappear from the cell surface (Fig. lB) ,  so that  after 60- 
120 min, net [3H]NMS binding loss was intermediate between 
the wild type and d 267-293 (differences among curves signif- 
icant, p c 0.05). We then compared the time course of [3H] 
NMS binding loss for the smallest deficient deletion mutant 
(d 284-293) with that of the wild-type Hml receptor (Fig. 2). 
Whereas wild-type Hml again internalized rapidly over the 
first 15 min, measurable [3H]NMS binding loss to -80% of 
control occurred after only 1-2 h for d 284-293. This behavior 
of d 284-293 is similar to  that of the intermediate deletion 
mutants, whereas the overall extent of [3H]NMS binding loss 
over 2 h was variable. 
Lack of Evidence for Role of Receptor Ser  and  Thr Phos- 
phorylation in Internalization-A series of Ser and  Thr mu- 
tations of Hrnl were constructed to  test whether phosphoryl- 
ation of any of these  sites plays a role in receptor internali- 
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FIG. 1. Time course of carbachol-induced loss of [3H]NMS- 
binding sites of Hml and selected mutants. Transiently  trans- 
fected U293 cells were incubated with 1 mM carbachol for 15-120 
min,  and ["HINMS (1.5 nM) binding was measured after carbachol 
removal. For comparison, the wild-type Hml  data were plotted in 
both A and B. Error bars are +S.D., with n = 4, except for mutants 
d 232-358 and d 267-293, where n = 10-16 (several experiments were 
pooled). 
0 30 60 90 1 2 0  150 
Time (min) 
FIG. 2. Time course of carbachol-induced loss of [3H]NMS- 
binding sites of Hml and smallest deletion mutant with defi- 
cient internalization (d 284-293). The experiment was per- 
formed as described for Fig. 1. Error bars are fS.D. ( n  = 4). 
TABLE I1
Mutations of Ser  and Thr residues in Hrnl 
Transiently  transfected U293 cells were exposed to 1 mM carbachol 
for 2 h (or 30 min  for T215A and T330A), and  [3H]NMS binding was 
measured. Overall [3H]NMS binding was comparable to  that of wild- 
type Hml-transfected cells for  each mutant. 
['HINMS binding (?S.D., n = 6 )  
% of control 
T215A 55 f 4 
S228A 52 f 4 
S322A 52 f 2 
T330A 56 k 7 
T354A 62 f 7,58 f 13,55 f 4 
S356A 60 f 7,64 f 3 
S368A 58 f 4 
T428A 53 f 4 
zation (Table 11). Replacement of Ser and  Thr  at various sites 
of Hml with Ala  did not significantly affect carbachol-induced 
internalization. Three  Ser/Thr residues in the COOH-termi- 
nal tail were eliminated by truncation at Lys447, with no effect 
on the  extent  or  rate of agonist-induced internalization (see 
above). 
DISCUSSION 
Receptor Activation and Internalization-Our results shed 
further light on the steps required for Hml receptor internal- 
ization following agonist exposure. The finding that  the non- 
functional receptor mutant D71N (23) does not undergo ago- 
nist-induced internalization/sequestration suggests that 
receptor activation (but not necessarily G protein  activation) 
is essential to  this process. Previous work with &-receptors, 
on the  other  hand, had suggested that receptor internaliza- 
tion/sequestration still proceeds even if the receptors are 
functionally uncoupled from the second messenger pathway 
(9,lO). Indeed, independent  activation of protein kinase C by 
PMA and enhancement of Ca2+ flux by  A23187 had no effect 
on [3H]NMS binding to cell-surface receptor in U293 cells, 
suggesting that these downstream events of PI turnover do 
not play a role in receptor internalization/sequestration in 
this case. 
The hypothesis of Cheung et al. (8) that  the receptor regions 
involved in functional coupling to G. are also required for 
agonist-promoted sequestration does not apply to  the  Hml 
receptor as we were able to construct numerous mutants 
deficient in sequestration/internalization, but still maximally 
active in stimulating PI turnover. The failure of pertussis 
toxin to suppress both PI turnover and sequestration/inter- 
nalization demonstrates that  the G protein involved in acti- 
vation is pertussis  toxin-insensitive. Whereas internalization 
of the &receptor was found to involve internalization from 
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its G  protein  (29),  a muscarinic receptor internalized in  astro- 
cytoma cells as a  G  protein-receptor complex (1 1). Because of 
these divergent results, it is currently  not possible to deter- 
mine whether activation of the associated G  protein is also 
required for agonist-induced internalization of Hml. 
COOH-terminal Tail of Hml  and  SerlThr Phosphorylation 
Sites-No evidence for an involvement of the COOH-terminal 
tail  (truncated  at in receptor internalization was evi- 
dent.  Point mutation of Thr4" to yield T428A further ascer- 
tained that none of the Ser/Thr residues in the COOH- 
terminal  tail plays an essential role in this process. Similarly, 
the lack of a role of the larger COOH-terminal tail of the &- 
receptor in internalization/sequestration was suggested by 
Strader et al. (31), and removal of Ser/Thr phosphorylation 
sites affected &receptor desensitization, but not internali- 
zation (10, 32). Our subsequent studies  therefore focused on 
the i3 loop of Hml. 
Deletion Mutations of i3 Loop of Hml-On the basis of our 
previous results that large deletions of the i3 loop impair Hml 
internalization  (22), we constructed  a series of deletion mu- 
tants by Bal-31 digestion from the  StuI site to define 
the responsible receptor domain(s) (see Fig. 3 for the i3 
sequence). All  of these deletions impaired internalization, and 
two rather small deletions in the middle of the i3 loop (d 267- 
292 and d 267-293)  allowed only a minimal degree of inter- 
nalization, suggesting that receptor sequence 267-292 con- 
tains a domain responsible for rapid internalization. This 
region can be further narrowed to domain 284-292 (Fig. 3) 
because of the wild-type behavior of the adjacent  small dele- 
tion mutants (d 265-274 and d 276-282) and the strongly 
impaired internalization of d 284-293  (GlyZs3  was reintroduced 
by an inverse polymerase chain  reaction) (Fig. 2). The general 
significance of this sequence will  be discussed at  the  end of 
this paper. 
Lack of net internalization of d 232-358, compared with 
the partial defect of other deletion mutants, suggested a 
possible role of either sequence 219-231 to inhibit net  inter- 
nalization or of sequence 349-358 to promote  a slow internal- 
FIG. 3. Graphic representation of i3 loop of Hml (TyrZos- 
Thr""). The cloverleaf design  does not imply any  secondary  struc- 
ture of the i3 loop. The region proposed to be involved in regulating 
receptor internalization is highlighted. TMD, transmembrane do- 
main. 
ization process. However, deletion of sequences 219-231 or d 
344-358 from wild-type Hml or from several internalization- 
defective mutants failed to affect the behavior of either the 
wild type or defective mutants (Table I). Therefore, sequences 
219-231 and 349-358 do not appear to play a direct role  in 
receptor trafficking; however, any  function  in modulating the 
wild-type behavior cannot yet be ruled out. 
A paradoxical result arose with the finding that  the  inter- 
nalization of d 232-358 and d 267-293 was either  absent or 
barely detectable, whereas the intermediate mutants showed 
appreciable net loss of [3H]NMS-binding sites over 2 h of 
carbachol exposure. A  study of the time course of internali- 
zation indicated that  the intermediate deletion mutants equil- 
ibrated more slowly during carbachol stimulation (Fig. 1) SO 
that the initial rates of internalization were considerably 
slower than those of wild-type Hml.  The large difference in 
the initial rate of [3H]NMS binding loss is best seen when 
comparing d 284-293 and wild-type Hml (Fig. 2). However, 
overall net loss of [3H]NMS binding loss over 2 h could 
approach that of the wild type (see d 220-314 in  Table I). It 
is therefore possible that  the internalization defect was not 
recognized in a previous report describing similar deletion 
mutants (21). The slow kinetic behavior of the intermediate 
deletion mutant is consistent with the hypothesis of an i3 
region playing a role in receptor recycling, and such a region 
may be located immediately adjacent to d 267-293. Consid- 
ering the location of all intermediate deletions, a putative 
region directing  a recycling process can be narrowed to se- 
quence 256-266 or 294-303. The deletion mutants d 256-293 
and d 283-303 were constructed to  test  this hypothesis, but 
they also showed an intermediate degree of receptor internal- 
ization, as did the small deletion mutant d 284-293. Therefore, 
the most defective mutants  (d 232-358 and d 267-293 (and d 
267-292)) showed an anomalous behavior that could not be 
definitively traced to any discrete domain of the i3 loop. It is 
possible that more than one mechanism contributes to  the 
loss of [3H]NMS binding from the cell's surface. Overall, the 
only deletion consistently associated with defective internal- 
ization in each case was domain 284-292. Deletions cause 
changes in the receptor structure that can account for the 
observed phenotypic changes; however, because of the large 
variety of deletions analyzed, rather strong evidence impli- 
cates domain 284-292 as being required in cellular processing 
of Hml. 
Significance of Domain 284-292 in Hml Cellular  Traffick- 
ing-This report is the first to propose a discrete receptor 
domain to be involved in agonist-induced receptor internali- 
zation/sequestration for any of the numerous G protein- 
coupled receptor (GPCRs).  In  contrast  to  the case of the low 
density lipoprotein receptor and growth factor receptors that 
carry such domains adjacent to  their transmembrane helix 
(1-6), the  Hml domain is located in the middle of the large 
i3 loop (Fig. 2). Among the cloned GPCRs, the i3 loop is 
highly diverse in sequence and size; therefore, applicability of 
this proposed domain to GPCR trafficking in general is not 
immediately obvious.  On the  other hand, there are also pro- 
nounced differences in the response of various GPCRs to 
agonist exposure, ranging from no detectable internalization 
to rapid and profound receptor loss from the surface and  the 
cell (e.g. Ref. 33). One would therefore  not expect functional 
domains involved in trafficking in each GPCR. 
The location of domain 284-292 is surprising because little 
overall sequence identity can be observed for the i3 loop  even 
among closely related  GPCRs  (34), and yet the various mus- 
carinic receptor subtypes  are all known to undergo internali- 
zation (35). Careful sequence comparison of the middle do- 
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FIG. 4. Sequence of domain 284-292 in  Hml aligned with 
similar sequences in Hm2-Hm5, also located in the middle of 
their respective i3 loops. 
main of the i3 loop reveals a low but detectable degree of 
identity, already noted before (35), with the presence of mul- 
tiple Ser and Thr residues (Fig. 4). Serine 284 of Hml is 
present in equivalent positions in Hm2-Hm5, and 2  amino 
acids downstream, there is a box of 5  amino acids with 3-5 
Ser  and  Thr residues. It is therefore possible that  the  inter- 
nalization domain identified in Hml is also functional in 
other muscarinic subtypes, and  it may have been introduced 
by shuffling of small exons. In fact, when introns occur in 
GPCR genes, they are usually found in the i3 loop. For 
example, a Drosophila muscarinic receptor gene contains 
three  introns in the i3 loop (36). Thus, functional domains 
could have been added from different gene fragments, and we 
will test  the general relevance of domain 284-292  of Hrnl for 
other GPCRs. 
The presence of multiple Ser and  Thr residues suggests the 
possibility that phosphorylation  events may play a role in  the 
internalization process. Hausdorff et dl. (30) have recently 
identified several Ser and  Thr residues of a proximal portion 
of the carboxyl-terminal tail of the &adrenoceptor (mutant 
S355-364) that  are involved in its rapid regulation, including 
phosphorylation, desensitization, and sequestration. How- 
ever, in view  of further  Ser  and  Thr point mutations of the 
COOH-terminal  tail, these  authors suggested that sequence 
355-364 is not directly involved, but  rather is critical for the 
COOH-terminal tail  to assume a suitable conformation for 
these regulatory processes. I t  remains to be seen whether 
Hml domain 284-292 in the i3 loop is phosphorylated upon 
receptor activation to allow internalization to occur. Regions 
similar to domain 284-292 with multiple Ser and  Thr esidues 
are found in the i3 loop or COOH-terminal tail of many other 
G protein-coupled receptors. 
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